Life Science VCs Shifting to Later Stage

Published: 9/26/2011 12:27:13 PM

The FDA is making it harder to find limited partner investors in life science-oriented venture capital funds, according to a recent piece in the Wall Street Journal:

View article here

The posting uses the example of Frazier Healthcare Ventures, a Seattle, Washington-based firm that is focused exclusively on life sciences.

The veteran firm is noting that it will increase the percentage devoted to later stage deals at the expense of earlier stage deals, reflecting the general wariness of investing in high risk, early-stage medical technologies.



Don Jones
CEO, VentureDeal

Blog Home

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.

RSS Feeds

Add this page to your RSS aggregator page with a simple click of a button below.

Add to My Yahoo! Add to Netvibes